• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chen Wei Wei

    6/23/23 4:23:09 PM ET
    $LIAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIAN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Chen Wei Wei

    (Last) (First) (Middle)
    C/O LIANBIO
    103 CARNEGIE CENTER DRIVE, SUITE 309

    (Street)
    PRINCETON NJ 08540

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LianBio [ LIAN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/21/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.4 06/21/2023 A 36,300 (1) 06/21/2033 Ordinary Shares 36,300 $0 36,300 D
    Explanation of Responses:
    1. The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.
    Remarks:
    By: /s/ Angela Chen, Attorney-in-Fact 06/23/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LIAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIAN

    DatePrice TargetRatingAnalyst
    1/3/2024$5.00 → $3.00Buy → Underperform
    BofA Securities
    12/22/2023$7.00 → $4.00Buy → Hold
    Jefferies
    More analyst ratings

    $LIAN
    SEC Filings

    See more
    • SEC Form 15-12G filed by LianBio

      15-12G - LianBio (0001831283) (Filer)

      3/21/24 8:00:10 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by LianBio

      EFFECT - LianBio (0001831283) (Filer)

      3/13/24 12:15:04 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-6 POS filed by LianBio

      F-6 POS - LianBio (0001831283) (Subject)

      3/12/24 8:30:54 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Appoints Wei Wei Chen to Board of Directors

      SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company's Board of Directors. "I am pleased to welcome Wei Wei Chen to the LianBio board," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "Her deep knowledge of the Chinese market, combined with her ability to manage business growth and transformation, will be extremely beneficial to LianBio as we grow our team and make strides toward advancing our diverse pipeline of potentially transformative medicines for patients

      4/7/22 8:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Financials

    Live finance-specific insights

    See more
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients

      • Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review EXPLORER-CN topline data and the China market opportunity for mavacamten on Monday, May 1 at 8:00 a.m. EDT / 8:00 p.m. CST SHANGHAI, China and PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to pati

      4/26/23 8:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LianBio downgraded by BofA Securities with a new price target

      BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously

      1/3/24 7:58:41 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio downgraded by Jefferies with a new price target

      Jefferies downgraded LianBio from Buy to Hold and set a new price target of $4.00 from $7.00 previously

      12/22/23 7:26:46 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gu Ehong sold $7,513 worth of Ordinary Shares (1,731 units at $4.34) and returned $5,724 worth of Ordinary Shares to the company (17,889 units at $0.32), closing all direct ownership in the company (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      4/11/24 4:10:11 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Poukalov Konstantin exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      2/20/24 5:27:03 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc exercised 72,600 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 38,436 units of Ordinary Shares (SEC Form 4)

      4 - LianBio (0001831283) (Issuer)

      2/20/24 5:25:28 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by LianBio (Amendment)

      SC 13D/A - LianBio (0001831283) (Subject)

      2/29/24 7:45:48 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by LianBio

      SC 13D - LianBio (0001831283) (Subject)

      11/30/23 5:08:48 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by LianBio

      SC 13G - LianBio (0001831283) (Subject)

      11/1/23 4:00:16 PM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care